ACTH release, 39 motor behavior nicotine prenatal/postnatal exposure

Affective disorders, 45 depression human growth hormone releasing

factor human studies plasma growth hormone levels

AIDS, 97 neuropeptide receptors primate brain T lymphocyte antigen

Alkalosis, 201 angiotensin II dogs drinking plasma osmolality

Angiotensin II, 201 alkalosis dogs drinking plasma osmolality

Anthropod peptides, 153 insect neuropeptides pigment-dispersing hormones structure-activity relationships

Arginine vasopressin, 193 drug interaction ethanol tolerance strain differences

Arginine-vasopressin levels, 109 cerebrospinal fluid circadian rhythm osmotic stimuli

Atrial natriuretic factor, 3 binding site regulation body fluid regulation brain, rat strain differences

Atrial natriuretic factor release, 189 clonidine water deprivation

Autonomic modulation, 63 cardiovascular activity opioid receptors sympathetic pathways

Autoradiography axonal transport, 85 IGF-II receptors, 91 IL-1 receptors, 91 immune system, 21 lymphocytes, 21 opiate receptors, 85 spleen, rat, 21 Thy 1.1 receptor distribution, 91 vasoactive intestinal peptide receptors,

21 Axonal transport, 85

autoradiography opiate receptors

Binding site regulation, 3 atrial natriuretic factor

V O L U M E 9 1988 S U P P L E M E N T 1

S U B J E C T I N D E X

body fluid regulation brain, rat strain differences

Biologically active conformations, 145 cerulein cholecystokinin conformational analysis Met-enkephalin little gastrin

Biosynthetic/proliferative capacity, 169 cultures intermediate lobe melanotroph morphology POMC gene expression

Blood pressure, 69 organ blood flow sympathetic nerve activity thryotropin releasing hormone

Body fluid regulation, 3 atrial natriuretic factor binding site regulation brain, rat strain differences

Bombesin dopaminergic system, 233, 245 grooming, 233, 245 locomotor activity, 233, 245 satiety, 233

Bombesin-like secretion, 257 cAMP levels small cell lung cancer somatostatin

Boxing behavior, 117 carbachol drug interaction prefrontal cortex substance P antagonists

Brain area postrema, 3, 21 cerebellar cortex, 18 l choroid plexus, 3 cranial nuclei, 21 dentate gyrus, 79, 181 dorsal motor nucleus of the vagus, 63 endopiriform cortex, 15 forebrain, 15 frontal cortex, 105 hindbrain, 63 hippocampus, 15, 79, 105, 181 hypothalamus, 15, 75, 105 intermediate lobe, 169 nucleus accumbens, 233,245 nucleus ambiguus, 63 nucleus tractus solitarius, 233, 245 olfactory bulb, 2 ! prefrontal cortex, 117 stria terminalis, 15 striatum, 105 subfornical organ, 3 thalamic nuclei, 21 thalamus, 15 ventral tegmental area, 223

Brain, rat atrial natriuretic factor, 3 binding site, regulation, 3 body fluid regulation, 3

radioimmunohistochemistry localization, 181

strain differences, 3 type II IGF receptors, 181

cAMP levels, 257 bombesin-like secretion small cell lung cancer somatostatin

Carbachol, 117 boxing behavior drug interaction prefrontal cortex substance P antagonists

Cardiovascular activity, 63 autonomic modulation opioid receptors sympathetic pathways

Cardiovascular system, 75 hypothalamus opioid receptors

CCK immunoreactivity, 79 mossy fiber neuropeptides neurotransmitter regulation seizures

Cell proliferation, 161 dopaminergic regulation intermediate lobe cultures POMC biosynthesis

Central nervous system, 9 dose-dependent effects gastric function thyrotropin releasing hormone ulceration

Cerebrospinal fluid, 109 arginine-vasopressin levels circadian rhythm osmotic stimuli

Cerulein, 145 biologically active conformations cholecystokinin conformational analysis Met-enkephalin little gastrin

Chemotaxis, 29 cholecystokinin human/rat monocyte comparisons immune system

Cholecystokinin biologically active conformations, 145 cerulein, 145 chemotaxis, 29 conformational analysis, 145 Met-enkephalin, 145 human/rat monocyte comparisons, 29 immune system, 29 little gastrin, 145

Cholecystokinin antagonists, 207 food intake satiety

Circadian rhythm, 109 arginine-vasopressin levels cerebrospinal fluid osmotic stimuli

Clonidine, 189

atrial natriuretic factor release water deprivation

Comparative distribution, 15 forebrain neuropeptide Y neuropeptide Y immunoreactivity receptor autoradiography

Conformational analysis, 145 biologically active conformations cerulein cholecystokinin Met-enkephalin little gastrin

Contractile strength, 215 motor unit performance nerve regeneration neuromuscular function ORG 2766

Cultures, 169 biosynthetic/proliferative capacity intermediate lobe melanotroph morphology POMC gene expression

Depression affective disorders, 45 growth hormone, 113 growth hormone-releasing factor, 113 human growth hormone releasing

factor, 45 human studies, 45 plasma growth hormone levels, 45

Dogs, 201 alkalosis angiotensin II drinking plasma osmolality

Dopaminergic regulation, 161 cell proliferation intermediate lobe cultures POMC biosynthesis

Dopaminergic system bombesin, 233,245 grooming, 233, 245 locomotor activity, 233. 245 satiety, 233

Dose-dependent effects, 9 central nervous system gastric function thyrotropin releasing hormone ulceration

Drinking dogs, 201 alkalosis, 201 angiotensin II, 201 plasma osmolality, 201

Drug acetylcholine, 117 atropine, 63 carbachol, 117 CR- 1409, 207 ethanol, 193 guanethidine, 63 haloperidol, 223 nicotine, 39 [Pen 1, pMePhe 2, Thr 4, OrnS]-OT, 223 pentylenetetrazol, 105 PGDPA, 207 proglumide, 207 RX 77368, 9 SCH 23390, 223

Drug interaction arginine vasopressin, 193 boxing behavior, 117 carbachol, 117 ethanol tolerance, 193 prefrontal cortex, 117 strain differences, 193 substance P antagonists, 117

Eating free-feeding rats, 35 growth hormone releasing factor, 35

Endogenous ligands, 49 multiple opioid receptors opioid actions review receptor dualism species differences

Met-Enkephalin, 145 biologically active conformations cerulein cholecystokinin conformational analysis little gastrin

Ethanol tolerar, ce, 193 arginine vasopressin drug interaction strain differences

FMRF-amide, 137 gastrin/CCK-like aspects leucosulfakinins structure-activity

FMRFamide-related peptides, 125 molluscan peptides

Food intake, 207 cholecystokinin antagonists satiety

Forebrain, 15 comparative distribution neuropeptide Y neuropeptide Y immunoreactivity receptor autoradiography

Free feeding rats, 35 eating growth hormone releasing factor

Gastric function, 9 central nervous system dose-dependent effects thyrotropin releasing hormone ulceration

Gastrin/CCK-like aspects, 137 FMRF-amide leucosulfakinins structure-activity

Grooming bombesin, 233, 245 dopaminergic system, 233, 245 locomotor activity, 245 oxytocin, 223 satiety, 233 ventral tegmental area, 223

Growth hormone, 113 depression growth hormone-releasing factor

Growth hormone-releasing factor depression, 113 eating, 35 free-feeding rats, 35

growth depression, 113

High affinity binding, 57 lung cancer cells neurotensin

Hormone ACTH, 39

Human growth hormone releasing factor, 45

affective disorders depression human studies plasma growth hormone levels

Human/rat monocyte comparisons, 29 chemotaxis cholecystokinin immune system

Human studies, 45 depression human growth hormone releasing

factor plasma growth hormone levels

Hypothalamus, 75 cardiovascular system opioid receptors

IGF-II receptors, 91 autoradiography IL-1 receptors Thy 1.1 receptor distribution

IL-1 receptors, 91 autoradiography IGF-II receptors Thy 1.1 receptor distribution

Immune system autoradiography, 21 chemotaxis, 29 cholecystokinin, 29 human/rat monocyte comparisons, 29 lymphocytes, 21 spleen, rat, 21 vasoactive intestinal peptide receptors,

21 Insect neuropeptides, 153

arthropod peptides pigment-dispersing hormones structure-activity relationships

Intermediate lobe, 169 biosynthetic/proliferative capacity cultures melanotroph morphology POMC gene expression

Intermediate lobe cultures, 161 cell proliferation dopaminergic regulation POMC biosynthesis

Kindling, pentylenetetrazol-induced, 105 pentylenetetrazol somatostatin-like immunoreactivity somatostatin receptor binding

Leucosulfakinins, 137 FMRF-amide gastrin/CCK-like aspects structure-activity

Little gastrin, 145 biologically active conformations cerulein cholecystokinin

mossy fiber neuropeptides neurotransmitter regulation

Small cell lung cancer, 257 bombesin-like secretion cAMP levels somatostatin

Somatostatin, 257 bombesin-like secretion cAMP levels small cell lung cancer

Somatostatin-like immunoreactivity, 105 kindling, pentylenetetrazol-induced pentylenetetrazol somatostatin receptor binding

Somatostatin receptor binding, 105 kindling, pentylenetetrazol-induced pentylenetetrazol somatostatin-like immunoreactivity

Species differences, 49 endogenous ligands multiple opioid receptors opioid actions review receptor dualism

Spleen, rat, 21 autoradiography immune system lymphocytes vasoactive intestinal peptide receptors

Strain differences arginine vasopressin, 193 atrial natriuretic factor, 3 binding site regulation, 3 body fluid regulation, 3 brain, rat, 3

drug interaction, 193 ethanol tolerance, 193

Structure-activity relationships arthropod peptides, 153 FMRF-amide, 137 gastrin/CCK-like aspects, 137 insect neuropeptides, 153 leucosulfakinins, 137 pigment-dispersing hormones, 153

Substance P antagonists, 117 boxing behavior carbachol drug interaction prefrontal cortex

Sympathetic nerve activity, 69 blood pressure organ blood flow thyrotropin releasing hormone

Sympathetic pathways, 63 autonomic modulation cardiovascular activity opioid receptors

Thy 1.1 receptor distribution, 91 autoradiography IGF-II receptors I1-1 receptors

Thyrotropin releasing hormone blood pressure, 69 central nervous system, 9 dose-dependent effects, 9 gastric function, 9 organ blood flow, 69

sympathetic nerve activity, 69 ulceration, 9

T lymphocyte antigen, 97 AIDS neuropeptide receptors primate brain

Type II IGF receptors, 181 brain, rat radioimmunohistochemistry

localization

Ulceration, 9 central nervous system dose-dependent effects gastric function thyrotropin releasing hormone

Vasoactive intestinal peptide receptors, 21 autoradiography immune system lymphocytes spleen, rat

Ventral tegmental area, 223 grooming behavior oxytocin

Water deprivation, 189 atrial natriuretic factor release clonidine

AUTHOR INDEX

Allen, A. E., 57 Amend, D. L., 193

Baranowska, B., 189 Bishop, J. F., 161, 169 Brief, D. J., 193 Broudy, E. P., 63

Carney, D. N., 57 Carry, R. P., 145 Chen, J., 145 Chronwall, B. M., 161, 169 Crawley, J. N., 117, 223

Dana, R., 45 Dorsa, D. M., 193

Ehlers, C., 45

Farrar, W. L., 97 Feifel, D., 35 Feuerstein, G., 75 Finan, T. M., 257

Gall, C. M., 79 Garrick, T., 9 Gehlert, D. R., 161, 169 Gillin, J. C., 45 Goto, Y., 9 Greenberg, M. J., 125 Gutkowska, J., 189

Haddon, W. F., 137 Hassen, A. H., 63 Hill, J. M., 21, 91, 97, 181 Hill, P. S., 223 Hjeresen, D. L., 193 Holman, G. M., 125, 137 Hruby, V. J., 223

Jamshaid, A., 201 Janowsky, D. S., 45 Johnston, S. A., 233,245 Jolkkonen, J., 105, 109 Judd, L., 45

Kaltwasser, M. T., 223 Kee, K. A., 257 Kiess, W., 181 King, J. A., 39 Koob, G. F., 35 Korman, L. Y., 257 Krishnan, K. R. R., 113 Kucharczyk, J., 201

Liifirii, E., 109 Lauterborn, J. C., 79 Lemoine, J., 201 Lesniak, M. A., 91, 181

McAdams, L. A., 45 McCarty, R., 3 McLean, S., 85

Maeda-Hagiwara, M., 9 Manepalli, A. N., 113 Martel, J.-C., 15 Melville, M. L., 113 Merali, Z., 233, 245 Moody, T. W., 57,257 Murphy, R. B., 145, 207

Nachman, R. J., 125, 137 Nemeroff, C. B., 113 Nissley, S. P., 181

Payza, K., 125 Pert, C. B., 21, 29, 91, 97 Pico, R. M., 79 Pincus, M. R., 145 Pitk/inen, A., 105 Plunkett, L. M., 3 Price, D. A., 125

Quirion, R., 15

Rao, K. R., 153 Rayasam, K., 113 Riehm, J. P., 153 Riekkinen, P., 105, 109 Risch, S. C., 45 Ritchie, J. C., 113 Rivier, J. E., 35, 113 Ruff, M. R., 29

Ruscetti, F., 97

Sacerdote, P., 29 Saint-Come, C. M., 215 Schafer, M. P., 161 Scheraga, H. A., 145 Schneider, L. H., 207 Sertl, K., 21 Shah, D., 145 Sir~.-L., 69, 75 Sirvi6, J., 105 Smith, G. P., 207 Stivers, J. A., 117, 223 St-Pierre, S., 15 Strand, F. L., 39, 215

Tachr, Y., 9 Thorner, M. O., 113 Tremblay, J., 189 Tumisto, L., 109

Vaccarino, F. J., 35 Vale, W. W., 35, 113 Van Wimersma Griedanus,

Tj. B., 109

Wiedermann, C. J., 21 Wood, P. L., 49 Woods, S. C., 193

Zipser, B., 21

conformational analysis Met-enkephalin

Locomotor activity, 245 bombesin dopaminergic system grooming

Lung cancer cells, 57 high affinity binding neurotensin

Lymphocytes, 21 autoradiography immune system spleen, rat vasoactive intestinal peptide receptors

Melanotroph morphology, 169 biosynthetic/proliferative capacity cultures intermediate lobe POMC gene expression

Method autoradiography, 21, 85, 91 immunocytochemistry, 79 immunohistochemistry, 169 quantitative autoradiography, 3 radioimmunoassay, 125, 169 radioimmunohistochemistry, 181

Molluscan peptides, 125 FMRFamide-related peptides

Mossy fiber neuropeptides, 79 CCK immunoreactivity neurotransmitter regulation seizures

Motor behavior, 39 ACTH release nicotine prenatal/postnatal exposure

Motor unit performance, 215 contractile strength nerve regeneration neuromuscular function ORG 2766

Multiple opioid receptors, 49 endogenous ligands opioid actions review receptor dualism species differences

Nerve regeneration, 215 contractile strength motor unit performance neuromuscular function ORG 2766

Neuromuscular function, 215 contractile strength motor unit performance nerve regeneration ORG 2766

Neuropeptide receptors, 97 AIDS primate brain T lymphocyte antigen

Neuropeptide Y, 15 comparative distribution forebrain neuropeptide Y immunoreactivity receptor autoradiography

Neuropeptide Y immunoreactivity, 15 comparative distribution forebrain

neuropeptide Y receptor autoradiography

Neurotensin, 57 high affinity binding lung cancer cells

Neurotransmitter regulation, 79 CCK immunoreactivity mossy fiber neuropeptides seizures

Nicotine, 39 ACTH release motor behavior prenatal/postnatal exposure

Opioid actions review, 49 endogenous ligands multiple opioid receptors receptor dualism species differences

Opioid receptors autonomic modulation, 63 autoradiography, 85 axonal transport, 85 cardiovascular activity, 63 cardiovascular system, 75 hypothalamus, 75 sympathetic pathways, 63

ORG 2766, 215 contractile strength motor unit performance nerve regeneration neuromuscular function

Organ blood flow, 69 blood pressure sympathetic nerve activity thyrotropin releasing hormone

Osmotic stimuli, 109 arginine-vasopressin levels cerebrospinal fluid circadian rhythm

Oxytocin, 223 grooming behavior ventral tegmental area

Pentylenetetrazol, 105 kindling, pentylenetetrazol-induced somatostatin-like immunoreactivity somatostatin receptor binding

Peptide angiotensin II, 201 arginine vasopressin, 109, 193 atrial natriuretic factor, 3 bombesin, 207, 233, 245 cerulein, 145 cholecystokinin, 29, 79, 137, 145,207 dynorphins, 75, 79 endorphins, 75 Met-enkephalin, 145 Met-enkephalin-Arg~-Phe r, 137 enkephalins, 75, 79 FMRF-amide, 137 gastrin, 137 growth hormone, 113 growth hormone releasing factor, 35,

113 human growth hormone releasing

factor, 45 leucosulfakinin, 137 little gastrin, 145 neuropeptide Y, 15

neurotensin, 57 ORG 2766, 215 oxytocin, 223 proopiomelanocortin, 161 somatostatin, 257 substance P, 117 thyrotropin releasing hormone, 9, 69 vasoactive intestinal peptide, 21 vasopressin, 189

Pigment-dispersing hormones, 153 arthropod peptides insect neuropeptides structure-activity relationships

Plasma growth hormone levels, 45 affective disorders depression human growth hormone releasing

factor human studies

Plasma osmolality, 201 alkalosis angiotensin 1I dogs drinking

POMC biosynthesis, 161 cell proliferation dopaminergic regulation intermediate lobe cultures

POMC gene expression, 169 biosynthetic/proliferative capacity cultures intermediate lobe melanotroph morphology

Prefrontal cortex, 117 boxing behavior carbachol drug interaction substance P antagonists

Prenatal/postnatal exposure, 39 ACTH release motor behavior nicotine

Primate brain, 97 AIDS neuropeptide receptors T lymphocyte antigen

Radioimmunohistochemistry localization, 181

brain, rat type II IGF receptors

Receptor autoradiography, 15 comparative distribution forebrain neuropeptide Y neuropeptide Y immunoreactivity

Receptor dualism, 49 endogenous ligands multiple opioid receptors opioid actions review species differences

Satiety bombesin, 233 cholecystokinin antagonists, 207 dopaminergic system, 233 food intake, 207 grooming, 233

Seizures, 79 CCK immunoreactivity